Silo Pharma, Inc. quarterly report, Q3 FY2017

SEC Filing Summary: Point Capital, Inc. (10-Q)

Business Context and Reporting Period

This filing is a Quarterly Report (Form 10-Q) for Point Capital, Inc., a closed-end, non-diversified Business Development Company (BDC), for the period ended September 30, 2017. The company invests in common stock, preferred stock, warrants, and convertible notes of small and mid-cap companies. As of the reporting date, the company held 16 portfolio companies, all classified as non-controlled and non-affiliated. The company is currently considering strategic options including liquidation, merger, or withdrawal of its BDC election.

Key Financial Metrics

Metric Sept 30, 2017 Dec 31, 2016
Total Assets $1,426,555 $1,299,604
Net Assets $996,158 $846,506
Cash and Cash Equivalents $301,690 $579,209
Investments at Fair Value $1,064,005 $634,873
Net Asset Value (NAV) per Share $0.02 $0.02
Redeemable Preferred Stock $400,000 $400,000

Results of Operations (Nine Months Ended Sept 30, 2017):

  • Total Investment Income: $20,478 (Interest income only).
  • Total Operating Expenses: $321,533 (including $135,000 in compensation and $129,567 in professional fees).
  • Net Investment Loss: $(301,055).
  • Net Realized Loss on Investments: $(79,879).
  • Net Unrealized Gain on Investments: $530,586.
  • Net Increase in Net Assets from Operations: $149,652.

Material Changes vs. Prior Period

  • Portfolio Valuation: The fair value of investments increased significantly from $634,873 to $1,064,005, driven primarily by a revaluation of the IPSIDY INC. position following the conversion of debt to equity.
  • Cash Position: Cash and cash equivalents decreased by $277,519 (48%) due to operating cash outflows used to pay professional fees and compensation.
  • Operating Expenses: Total operating expenses for the nine-month period decreased by $46,085 compared to the prior year, primarily due to reduced legal and accounting fees, despite a 38.5% increase in compensation expense.
  • Investment Composition: Biometric Technology now represents 66.44% of the portfolio (up from 25.33%), concentrated heavily in IPSIDY INC.

Guidance, Outlook, Risks, and Unusual Items

Tax Status Change (Critical): Since March 31, 2017, the company failed the RIC diversification test because its investment in IPSIDY INC. exceeded 25% of total assets (reaching 49.6% by Sept 30, 2017). The company has not cured this failure and does not intend to retain its status as a Regulated Investment Company (RIC). Consequently, the company is now subject to corporate-level income taxes.

Strategic Outlook: Management is evaluating options including liquidation, merger with another BDC or operating company, or withdrawing its BDC election to pursue operating company status. No definitive plan has been executed yet.

Internal Controls: The company disclosed that its disclosure controls and procedures were ineffective as of September 30, 2017. Material weaknesses include a lack of segregation of duties, lack of Investment Act experienced staff, and lack of control over the valuation of certain investments.

Liquidity: The company believes existing cash will meet working capital requirements for at least 12 months but has no agreements to raise capital. Future operations may require additional equity or debt financing, which could result in dilution.

Investor Verification Checklist

  • RIC Status Loss: Verify the impact of losing RIC status on future tax liabilities and net asset value, as the company is now subject to corporate tax rates.
  • Concentration Risk: Confirm the valuation methodology and liquidity of the IPSIDY INC. holding, which comprises nearly 50% of total assets and 71% of the investment portfolio.
  • Internal Control Weaknesses: Assess the remediation plan for the material weaknesses in internal controls over financial reporting and disclosure.
  • Preferred Stock Triggers: Review the terms of the $400,000 Series A Convertible Preferred Stock, specifically the "triggering events" that could force redemption or dividend accruals.
  • Cash Burn Rate: Monitor the cash balance ($301,690) against the monthly operating burn rate to determine the runway before additional capital is required.